One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, OneMap, aimed at transforming cancer diagnostics and treatment.
The round was led by Redmile Group and Blast, with support from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures.
OneMap generates detailed functional profiles of patient tumours, helping guide treatment decisions, improve patient selection and optimise clinical trials. The funding will support clinical development and scale strategic partnerships with pharma and biotech firms.
Hedi Ben Brahim, CEO of One Biosciences, said: “This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development.”
Dr Céline Vallot, Co-Founder and group leader at Curie Institute, added: “This investment coupled with our established capacity to train our AI algorithms with proprietary single-cell patient datasets will further substantiate our ability to predict the response to most classes of oncology therapeutics from clinical grade specimens.”
Dr Mehdi Touat, Assistant Professor at Assistance Publique – Hôpitaux de Paris AP-HP and Paris Brain Institute, said: “Widespread use of next generation sequencing profiling has led to substantial advances in cancer care but the clinical benefit remains limited to small patient subsets. We believe clinical grade single cell profiling has the potential to catalyse the next generation of diagnostic and therapeutic advances.”
The new funding brings One Biosciences’ total raised to over €20 million, including seed financing from Home Biosciences. The company aims to position OneMap as a clinical tool to support precision oncology and drive innovation in cancer care.
